RE: Home Use21 Jul 2021 16:47
CE mark and product registration in EU and UK received. •
Global Access Diagnostics Ltd (GAD) manufacturing commercial product. •
Abingdon Health plc (LON: ABDX) establishing manufacturing processes equivalent to GAD’s.
• BBI Solutions could not deliver in terms of time/cost of goods (COGs). •
Ongoing negotiations with other UK, EU and overseas manufacturers to achieve volume and required COGs. •
Combined UK manufacturing capacity when fully scaled-up that is available to Avacta (depending on access to equipment funded by HM Government) is 5 –30 million tests per month from Q3.
• Additional overseas capacity can provide up to 1 million tests per day with short (6-8 weeks) technology transfer time and lower COGs.
Multiple commercial negotiations with distributors and end users ongoing in EU and UK for professional use test. •
Avacta direct sales activity is targeting:–large corporates for workforce testing;–work-force testing service providers;–travel related businesses (airlines, airports);–events companies;–care homes and other social and healthcare businesses required to test their employees. •
First distribution partnership now in place with Calibre Scientific:–Non-exclusive distribution agreement serving EU and UK. •
Avacta remains engaged with the UK government procurement pathway through Porton Down1. •
Other overseas non-EU customers/distributors in discussion.
Diagnostics: substantial opportunity for AffiDX® rapid antigen test
• Multiple commercial deals with distributors and end users expected in H2.
• Demand for rapid COVID-19 testing expected to remain high for years.
• Strong pipeline of non-COVID diagnostic tests in development.
There we go that's what we know
Sign In
Follow the stocks
